Starling Oncology, Inc. (STLNW) Revenue 2020–2025
Starling Oncology, Inc. (STLNW) annual revenue history from SEC filings — each fiscal year as reported, with year-over-year change.
$502.7MFY2025 · since FY2020: $187.5M → $502.7M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $502.7M | +27.8% |
| FY2024 | $393.4M | +21.3% |
| FY2023 | $324.2M | +28.4% |
| FY2022 | $252.5M | +24.4% |
| FY2021 | $203.0M | +8.3% |
| FY2020 | $187.5M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More STLNW financial trends
STLNW Net incomeSTLNW Net marginSTLNW Gross profitSTLNW Gross marginSTLNW Operating incomeSTLNW Operating marginSTLNW Operating cash flowSTLNW Free cash flowSTLNW Capital expendituresSTLNW Return on equitySTLNW Stock buybacksSTLNW Dividends paidSTLNW Total assetsSTLNW Total liabilitiesSTLNW Shareholders’ equitySTLNW overview →